Furthermore, ML techniques have been integrated into the discovery of anti-obesity compounds with GR antagonist activity, leveraging structural and pharmacokinetic data to refine candidate selection16. The gene discussed is NR3C1; the disease is obesity due to melanocortin 4 receptor deficiency.